258 related articles for article (PubMed ID: 16973883)
41. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys.
Zia-Amirhosseini P; Minthorn E; Benincosa LJ; Hart TK; Hottenstein CS; Tobia LA; Davis CB
J Pharmacol Exp Ther; 1999 Dec; 291(3):1060-7. PubMed ID: 10565825
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetic and pharmacodynamic studies following oral administration of erythropoietin mucoadhesive tablets to beagle dogs.
Venkatesan N; Yoshimitsu J; Ohashi Y; Ito Y; Sugioka N; Shibata N; Takada K
Int J Pharm; 2006 Mar; 310(1-2):46-52. PubMed ID: 16439074
[TBL] [Abstract][Full Text] [Related]
43. Effects of short-term administration of recombinant human erythropoietin on rat megakaryopoiesis.
Yonemura Y; Kawakita M; Fujimoto K; Sakaguchi M; Kusuyama T; Hirose J; Kato K; Takatsuki K
Int J Cell Cloning; 1992 Jan; 10(1):18-27. PubMed ID: 1552221
[TBL] [Abstract][Full Text] [Related]
44. Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia.
Bowen D; Hyslop A; Keenan N; Groves M; Culligan D; Johnson P; Shaw A; Geddes F; Evans P; Porter J; Cavill I
Haematologica; 2006 May; 91(5):709-10. PubMed ID: 16670077
[TBL] [Abstract][Full Text] [Related]
45. Analysis of human reticulocyte genes reveals altered erythropoiesis: potential use to detect recombinant human erythropoietin doping.
Varlet-Marie E; Audran M; Lejeune M; Bonafoux B; Sicart MT; Marti J; Piquemal D; Commes T
Haematologica; 2004 Aug; 89(8):991-7. PubMed ID: 15339684
[TBL] [Abstract][Full Text] [Related]
46. The effect of common hematologic abnormalities on the ability of blood models to detect erythropoietin abuse by athletes.
Parisotto R; Ashenden MJ; Gore CJ; Sharpe K; Hopkins W; Hahn AG
Haematologica; 2003 Aug; 88(8):931-40. PubMed ID: 12935982
[TBL] [Abstract][Full Text] [Related]
47. Development of reference ranges in elite athletes for markers of altered erythropoiesis.
Sharpe K; Hopkins W; Emslie KR; Howe C; Trout GJ; Kazlauskas R; Ashenden MJ; Gore CJ; Parisotto R; Hahn AG
Haematologica; 2002 Dec; 87(12):1248-57. PubMed ID: 12495898
[TBL] [Abstract][Full Text] [Related]
48. Interferon-gamma mediates suppression of erythropoiesis but not reduced red cell survival following CpG-ODN administration in vivo.
Thawani N; Tam M; Chang KH; Stevenson MM
Exp Hematol; 2006 Nov; 34(11):1451-61. PubMed ID: 17046564
[TBL] [Abstract][Full Text] [Related]
49. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO).
Woo S; Krzyzanski W; Jusko WJ
J Pharmacokinet Pharmacodyn; 2007 Dec; 34(6):849-68. PubMed ID: 17943422
[TBL] [Abstract][Full Text] [Related]
50. [Recombinant human erythropoietin: method of in vivo evaluation using normocythemic mice].
Albertengo ME; Valcarce GA; Oliva LM; Baiges DL; Alonso BS; Chiale CA
Sangre (Barc); 1999 Oct; 44(5):357-63. PubMed ID: 10618913
[TBL] [Abstract][Full Text] [Related]
51. Enterally dosed recombinant human erythropoietin does not stimulate erythropoiesis in neonates.
Juul SE
J Pediatr; 2003 Sep; 143(3):321-6. PubMed ID: 14517513
[TBL] [Abstract][Full Text] [Related]
52. Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: results of a double-blind, placebo-controlled randomized trial.
Tang YD; Rinder HM; Katz SD
Am Heart J; 2007 Sep; 154(3):494.e1-7. PubMed ID: 17719296
[TBL] [Abstract][Full Text] [Related]
53. Gestational age dependency in the prenatal toxicity and in the disposition kinetics of the novel anticonvulsant HEPP (D,L-3-hydroxy-3-ethyl-3-phenylpropionamide) after subcutaneous administration in pregnant rats.
Gómez-Martínez LE
Int J Toxicol; 2007; 26(3):237-46. PubMed ID: 17564905
[TBL] [Abstract][Full Text] [Related]
54. Lymphatic absorption is the primary contributor to the systemic availability of epoetin Alfa following subcutaneous administration to sheep.
McLennan DN; Porter CJ; Edwards GA; Martin SW; Heatherington AC; Charman SA
J Pharmacol Exp Ther; 2005 Apr; 313(1):345-51. PubMed ID: 15579493
[TBL] [Abstract][Full Text] [Related]
55. Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma.
Katodritou E; Terpos E; Zervas K; Speletas M; Kapetanos D; Kartsios C; Verrou E; Banti A; Effraimidou S; Christakis J
Ann Hematol; 2007 May; 86(5):369-76. PubMed ID: 17375302
[TBL] [Abstract][Full Text] [Related]
56. A statistical pattern recognition approach for determining cellular viability and lineage phenotype in cultured cells and murine bone marrow.
Quinn J; Fisher PW; Capocasale RJ; Achuthanandam R; Kam M; Bugelski PJ; Hrebien L
Cytometry A; 2007 Aug; 71(8):612-24. PubMed ID: 17542025
[TBL] [Abstract][Full Text] [Related]
57. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats.
Kato M; Kamiyama H; Okazaki A; Kumaki K; Kato Y; Sugiyama Y
J Pharmacol Exp Ther; 1997 Nov; 283(2):520-7. PubMed ID: 9353365
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration.
Fishbane S; Pannier A; Liogier X; Jordan P; Dougherty FC; Reigner B
J Clin Pharmacol; 2007 Nov; 47(11):1390-7. PubMed ID: 17962427
[TBL] [Abstract][Full Text] [Related]
59. Aging of red blood cells and impaired erythropoiesis following prolonged administration of dichloromethylene diphosphonate containing liposomes in rats.
Giuliani AL; Graldi G; Veronesi M; Unis L; Previato A; Lorenzini F; Gandini G; Bergamini C; Vanara F; Wiener E; Wickramasinghe SN; Berti G
Eur J Haematol; 2005 Nov; 75(5):406-16. PubMed ID: 16191091
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
